The Maryland Technology Development Corporation (TEDCO) announced today that six companies, including Virtici spinout Rise Therapeutics, received a total of $800,000 in seed funding. 

Celdara Medical, LLC today announced that it has successfully concluded negotiations with Celyad SA (Euronext Brussels and Paris, and NASDAQ:CYAD) related to their ongoing partnership for discovery and development of CAR T cell therapies.

Virtici, LLC announced today the spin-out of a new drug development company, Rise Therapeutics, which is focused on developing microbiome-based, immunological therapies. To form the spin-out, Rise obtained key microbiome-related intellectual property and technologies incubated at Virtici to support the development of first-in-class, orally-delivered, biological medicines.

Today Virtici, Celdara Medical and MBV announced their formation of the first collaborative nationwide network for the development of early stage biotechnologies. The goals are simple: to improve human health by identifying the highest potential innovations in medicine and developing them into the clinic.

Cardio3 BioSciences (C3BS) (Euronext Brussels and Paris: CARD), a leader in the discovery and development of cell therapies, today announced the acquisition of OnCyte, LLC a division of Celdara Medical, and its portfolio of immuno-oncology CAR T cell product candidates.

Daiichi Sankyo, Co., Ltd., Virtici, LLC and Celdara Medical, LLC announced today that they have entered into a collaboration to jointly investigate novel therapeutic candidates and thereby further strengthen the Daiichi Sankyo developmental pipeline across multiple therapeutic areas.